

Quick to Clinic™ delivers Phase I clinical trial material, fast.

With Quick to Clinic™, Thermo Fisher Scientific can deliver your oral solid dose product to the Phase I clinic in as little as 14 weeks from API supply, including 1 month stability data. Now you can meet important milestones and ensure patients receive your discovery.... FAST!

High-quality Phase I clinical materials in as little as 14 weeks WEEK Receipt of API Prototype batches Stability (1 month) Analytical method verification API release CTM production Bulk release Stability (1 month CTM) Ship Clinical packaging & labeling QP Certification for clinical trial use (release to clinic)

Quick to Clinic[™] for Oral Solid Dose meets the needs of pharmaceutical companies big and small

Now you can generate Phase I data for your product as quickly as possible. Designed for speed, Quick to Clinic™ is also incredibly flexible. Our approach will deliver a Phase appropriate formulation, stability and full clinical labeling, packaging, and QP Certification for clinical trial use release and distribution. Our Quick to Clinic™ program is fast, flexible and full.



Fast

- QP released product to the clinic in as little as 14 weeks from API receipt
- Phase appropriate formulation
- Seamless manufacture, packing & QP services



Flexible

- Range of dose forms
- Seamless Project Management
- Technical expertise fast problem solving
- Reactive scheduling



E. .II

- 1 months IND/IMPD stability
- QP release to clinic

To deliver on-time, we offer enhanced project visibility and communication, combined with over 40 years of experience.

Why work with Thermo Fisher?

When it comes to oral solid dose Quick to Clinic™ materials, experience matters. We have an excellent track record in the industry and the ability to plug seamlessly into your clinical trial. We also support our technology and expertise with all the systems that make your project run smoothly, so you save time and money.

117 NDAs in the last 10 years – more than any other CDMO 300+ clinical batches manufactured in the last three years

95% On Time Delivery performance Extensive experience with emerging pharma – 60% of our clients are small / emerging companies End-to-end approach to gain speed by integrating planning and communication for drug product and clinical trial supply

